Silverback Therapeutics, Inc. (NASDAQ:SBTX - Get Free Report) shares were up 4.9% on Tuesday . The company traded as high as $16.59 and last traded at $16.57. Approximately 1,408,322 shares traded hands during mid-day trading, an increase of 317% from the average daily volume of 337,931 shares. The stock had previously closed at $15.80.
Silverback Therapeutics Stock Performance
The stock has a 50 day moving average of $14.40 and a two-hundred day moving average of $12.91. The stock has a market cap of $597.48 million, a PE ratio of -6.85 and a beta of 0.60.
About Silverback Therapeutics
(
Get Free Report)
Silverback Therapeutics, Inc, a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Silverback Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Silverback Therapeutics wasn't on the list.
While Silverback Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
